Q: Is retatrutide approved for use
How Payer Friction and Patient Drop-Off Undermine Obesity GLP-1 Uptake The GLP-1 market is experiencing unprecedented demand, yet despite its clinical promise for obesity, diabetes, and other conditions, patient behavior and friction throughout the treatment journey continue to erode its commercial potential
Fillon-Emery N, Chango A, Mircher C, Barb F, Blhaut H, Herbeth B, et al
Individuals taking benzos for several months or more and in high doses are likely to experience more withdrawal symptoms that last longer than those taking smaller doses for a shorter length of time
Or, if marketing implied Ozempic and Wegovy had the same results or testing for weight loss, this can support failure-to-warn lawsuits
1 2 Lauerman, Kerry (January 16, 2011)